Author

Theresa Laeder

Institutions: Metro Health Hospital, Michigan State University

Observed institutions: Metro Health Hospital, Massachusetts General Hospital, The Barbara Ann Karmanos Cancer Institute, Dana-Farber Cancer Institute, Michigan State University

OpenAlex ID: A5073768899

A Phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics of XL880, a VEGFR and MET kinase inhibitor, administered daily to patients (pts) with advanced malignancies

2007 · Geoffrey I. Shapiro, E. Heath, et al. · Molecular Cancer Therapeutics · 10

Utility and feasibility of ultrasound‐guided access in patients with critical limb ischemia

2012 · J.A. Mustapha, Fadi Saab, et al. · Catheterization and Cardiovascular Interventions · 7

Works count: 2

Citation count: 17

H-index: 2

I10-index: 1